Encala results

Encala has been clinically proven to help people with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI) improve overall fat and nutrient absorption

In a National Institutes of Health study, 110 people with CF and EPI added Encala to their meals, beverages, or snacks for one year.
Results showed that Encala helped people with CF and EPI absorb fat and other essential nutrients, allowing them to reach and maintain
weight, height, and body mass index (BMI) targets in a healthy way.

Who was studied

Children and adolescents 5 to 18 years of age with CF, currently taking pancreatic enzyme replacement therapy (PERT), and with mild to moderate lung disease were recruited from 10 CF centers.

How they were studied

For 1 year:

What the study measured

Encala’s effectiveness was measured by improvement in overall fat absorption, weight, height, and BMI increases.

Encala significantly improves overall fat absorption as measured by change in stool coefficient of fat absorption (CFA)

Encala was found to be effective and clinically proven to:

Encala was found to be safeIn the course of the study, Encala was found to be safe. It was also well-tolerated, which means it did not result in any significant side effects in the patients who received Encala.

Discover resources for people using Encala »​

Learn about reimbursement, coverage, and customer care for Encala.

See how easy it is to use Encala »

It’s a simple, convenient way to add healthy fat to your diet.

Scroll to Top